Safety and efficacy of nab paclitaxel in the treatment of patients with breast cancer

Prakash Vishnu, Vivek Roy

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Taxanes are highly active chemotherapeutic agents in the treatment of early stage and metastatic breast cancer. Novel formulations have been developed to improve efficacy and decrease toxicity associated with these cytotoxic agents. nab paclitaxel is a solvent free, albumin bound 130 nanometer particle formulation of paclitaxel (Abraxane®, Abraxis Bioscience), which was developed to avoid toxicities of the Cremophor vehicle used in solvent based paclitaxel. In a phase III clinical trial, nab paclitaxel demonstrated higher response rates, better safety and side effect profile compared to conventional paclitaxel, and improved survival in patients receiving it as second line therapy. Higher doses can be administered over a shorter infusion time without the need for special influ sion sets or pre medications. It is now approved in the US for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy, where prior therapy included an anthracycline. Recently, several phase II studies have suggested a role for nab paclitaxel as a single agent and in combination with other agents for first line treatment of metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)53-65
Number of pages13
JournalBreast Cancer: Basic and Clinical Research
Volume5
Issue number1
DOIs
StatePublished - Jun 13 2011

Fingerprint

Breast Neoplasms
Safety
Paclitaxel
Therapeutics
Taxoids
Phase III Clinical Trials
Anthracyclines
Cytotoxins
Combination Drug Therapy
130-nm albumin-bound paclitaxel
Albumins
Recurrence
Survival

Keywords

  • Metastatic breast cancer
  • Nab paclitaxel
  • Nab technology
  • Paclitaxel
  • Taxanes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Safety and efficacy of nab paclitaxel in the treatment of patients with breast cancer. / Vishnu, Prakash; Roy, Vivek.

In: Breast Cancer: Basic and Clinical Research, Vol. 5, No. 1, 13.06.2011, p. 53-65.

Research output: Contribution to journalReview article

@article{71ad79cb41c6411596cbe9ebc4b59fd2,
title = "Safety and efficacy of nab paclitaxel in the treatment of patients with breast cancer",
abstract = "Taxanes are highly active chemotherapeutic agents in the treatment of early stage and metastatic breast cancer. Novel formulations have been developed to improve efficacy and decrease toxicity associated with these cytotoxic agents. nab paclitaxel is a solvent free, albumin bound 130 nanometer particle formulation of paclitaxel (Abraxane{\circledR}, Abraxis Bioscience), which was developed to avoid toxicities of the Cremophor vehicle used in solvent based paclitaxel. In a phase III clinical trial, nab paclitaxel demonstrated higher response rates, better safety and side effect profile compared to conventional paclitaxel, and improved survival in patients receiving it as second line therapy. Higher doses can be administered over a shorter infusion time without the need for special influ sion sets or pre medications. It is now approved in the US for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy, where prior therapy included an anthracycline. Recently, several phase II studies have suggested a role for nab paclitaxel as a single agent and in combination with other agents for first line treatment of metastatic breast cancer.",
keywords = "Metastatic breast cancer, Nab paclitaxel, Nab technology, Paclitaxel, Taxanes",
author = "Prakash Vishnu and Vivek Roy",
year = "2011",
month = "6",
day = "13",
doi = "10.4137/BCBCR.S5857",
language = "English (US)",
volume = "5",
pages = "53--65",
journal = "Breast Cancer: Basic and Clinical Research",
issn = "1178-2234",
publisher = "Libertas Academica Ltd.",
number = "1",

}

TY - JOUR

T1 - Safety and efficacy of nab paclitaxel in the treatment of patients with breast cancer

AU - Vishnu, Prakash

AU - Roy, Vivek

PY - 2011/6/13

Y1 - 2011/6/13

N2 - Taxanes are highly active chemotherapeutic agents in the treatment of early stage and metastatic breast cancer. Novel formulations have been developed to improve efficacy and decrease toxicity associated with these cytotoxic agents. nab paclitaxel is a solvent free, albumin bound 130 nanometer particle formulation of paclitaxel (Abraxane®, Abraxis Bioscience), which was developed to avoid toxicities of the Cremophor vehicle used in solvent based paclitaxel. In a phase III clinical trial, nab paclitaxel demonstrated higher response rates, better safety and side effect profile compared to conventional paclitaxel, and improved survival in patients receiving it as second line therapy. Higher doses can be administered over a shorter infusion time without the need for special influ sion sets or pre medications. It is now approved in the US for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy, where prior therapy included an anthracycline. Recently, several phase II studies have suggested a role for nab paclitaxel as a single agent and in combination with other agents for first line treatment of metastatic breast cancer.

AB - Taxanes are highly active chemotherapeutic agents in the treatment of early stage and metastatic breast cancer. Novel formulations have been developed to improve efficacy and decrease toxicity associated with these cytotoxic agents. nab paclitaxel is a solvent free, albumin bound 130 nanometer particle formulation of paclitaxel (Abraxane®, Abraxis Bioscience), which was developed to avoid toxicities of the Cremophor vehicle used in solvent based paclitaxel. In a phase III clinical trial, nab paclitaxel demonstrated higher response rates, better safety and side effect profile compared to conventional paclitaxel, and improved survival in patients receiving it as second line therapy. Higher doses can be administered over a shorter infusion time without the need for special influ sion sets or pre medications. It is now approved in the US for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy, where prior therapy included an anthracycline. Recently, several phase II studies have suggested a role for nab paclitaxel as a single agent and in combination with other agents for first line treatment of metastatic breast cancer.

KW - Metastatic breast cancer

KW - Nab paclitaxel

KW - Nab technology

KW - Paclitaxel

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=79958100231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958100231&partnerID=8YFLogxK

U2 - 10.4137/BCBCR.S5857

DO - 10.4137/BCBCR.S5857

M3 - Review article

C2 - 21603258

AN - SCOPUS:79958100231

VL - 5

SP - 53

EP - 65

JO - Breast Cancer: Basic and Clinical Research

JF - Breast Cancer: Basic and Clinical Research

SN - 1178-2234

IS - 1

ER -